The Top 5 VC deals of the first half of 2007

Venture capital is the lifeblood of up-and-coming biotechs. In order to interest investors and keep the money coming in, biotechs must have a strong vision, promising pipeline and a management team that can guide a company through the rigorous drug development process. For a look at which biotechs have gained the most attention this year, check out the five promising companies that raised the most money in the first half of 2007.

 

Ception Therapeutics

Targanta Therapeutics

  Portola Pharmaceuticals

Novexel

Movetis

 

The Top 5 VC deals of the first half of 2007
Read more on

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.